VA

Venrock Adviser, LLC

Momentum followerQuality / disciplined sizing

Total reported value

$2.7B

Reporting period: 2026-03-31 · Number of holdings: 33

Venrock Adviser, LLC disclosed 33 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.7B and a quarterly turnover rate of 41.3%.

Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "V"

Personality snowflake

Concentration
41.5
Portfolio Stability
41.28
Momentum/Contrarian
100
Sector conviction
0
Diversification
66
Sizing Uniformity
84.19

Recent moves

  • Add ERAS

    -8.3%　$198.6M

  • Trim APGE

    0.0%　$73.8M

  • Trim VRDN

    0.0%　-$44.9M

  • Add DNTH

    +18.0%　$57.8M

  • Trim CTMX

    -35.9%　-$19.4M

  • Add ORKA

    0.0%　$77.7M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1APGEApogee Therapeutics INCStock-Other26.68%-4.99%—
2ERASErasca INCStock-Other9.89%+6.61%-8.26%
3ORKAOruka Therapeutics INCStock-Other7.60%+1.39%—
4SYRESpyre Therapeutics INCStock-Other6.94%+0.98%—
54XC1Kalvista Pharmaceuticals INCStock-Other4.86%-0.51%-3.78%
6DNTHDianthus Therapeutics INCStock-Other3.70%+1.66%+18.00%
7DMRADamora Therapeutics INCStock-Other3.48%+3.48%NEW
8OCULOcular Therapeutix INCStock-Other3.27%-1.12%+41.44%
9COGTCogent Biosciences INCStock-Other2.87%-0.64%—
10VRDNViridian Therapeutics INCStock-Other2.83%-3.14%—
11SVRASavara INCStock-Other2.80%-1.29%—
12ELVNEnliven Therapeutics INCStock-Other2.53%+0.08%-46.49%
13ORICOric Pharmaceuticals INCStock-Other2.04%-0.25%-23.90%
14VORVor Biopharma INCStock-Other2.03%+0.77%+56.49%
15MAZEMaze Therapeutics INCStock-Other1.78%-1.39%+3.45%
16CTMXCytomx Therapeutics INCStock-Other1.75%-1.52%-35.85%
17JBIOJade Biosciences INCStock-Other1.69%-0.76%—
18DYNDyne Therapeutics INCStock-Other1.47%-0.63%—
19✓ Crescent Biopharma INC.Stock-Other1.46%+0.21%—
20✓ Zura Bio LTDStock-Other1.43%+0.05%+20.39%
21RLMDRelmada Therapeutics INCStock-Other1.26%+1.26%NEW
22✓ Engene Holdings INCStock-Other1.21%-0.92%—
23TENXTenax Therapeutics INCStock-Other1.00%+1.00%NEW
24ANLAdlai Nortye Ltd-adrStock-Other0.83%+0.83%NEW
25IPSCCentury Therapeutics INCStock-Other0.73%+0.73%NEW
26CGEMCullinan Therapeutics INCStock-Other0.73%+0.02%—
27HELPCybin INCStock-Other0.69%-0.86%+0.30%
28SRZNSurrozen INCStock-Other0.69%-0.02%—
29SEPNSepterna INCStock-Other0.45%-0.39%-17.15%
30KRROKorro Bio INCStock-Other0.43%+0.43%NEW
31ANROAlto Neuroscience INCStock-Other0.42%+0.42%NEW
32ARTVArtiva Biotherapeutics INCStock-Other0.39%+0.05%—
33XFORX4 Pharmaceuticals INCStock-Other0.05%+0.05%NEW

Holding changes this quarter

Venrock Adviser, LLC's most significant position changes for 2026-03-31: New buy: Damora Therapeutics INC (DMRA); New buy: Relmada Therapeutics INC (RLMD); Sold out: Upstream Bio INC (UPB); New buy: Tenax Therapeutics INC (TENX); New buy: Adlai Nortye Ltd-adr (ANL).

Position changes disclosed by Venrock Adviser, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1ERASErasca INC+6.6%-8.26%Trim
2DNTHDianthus Therapeutics INC+1.7%+18.00%Add
3ORKAOruka Therapeutics INC+1.4%—Unchanged
4SYRESpyre Therapeutics INC+1%—Unchanged
5VORVor Biopharma INC+0.8%+56.49%Add
6✓ Crescent Biopharma INC.+0.2%—Unchanged
7ELVNEnliven Therapeutics INC+0.1%-46.49%Trim
8✓ Zura Bio LTD+0.1%+20.39%Add
9ARTVArtiva Biotherapeutics INC+0.1%—Unchanged
10CGEMCullinan Therapeutics INC0%—Unchanged
11SRZNSurrozen INC0%—Unchanged
12ORICOric Pharmaceuticals INC-0.3%-23.90%Trim
13SEPNSepterna INC-0.4%-17.15%Trim
144XC1Kalvista Pharmaceuticals INC-0.5%-3.78%Trim
15DYNDyne Therapeutics INC-0.6%—Unchanged
16COGTCogent Biosciences INC-0.6%—Unchanged
17JBIOJade Biosciences INC-0.8%—Unchanged
18HELPCybin INC-0.9%+0.30%Add
19✓ Engene Holdings INC-0.9%—Unchanged
20OCULOcular Therapeutix INC-1.1%+41.44%Add
21SVRASavara INC-1.3%—Unchanged
22MAZEMaze Therapeutics INC-1.4%+3.45%Add
23CTMXCytomx Therapeutics INC-1.5%-35.85%Trim
24VRDNViridian Therapeutics INC-3.1%—Unchanged
25APGEApogee Therapeutics INC-5%—Unchanged
26DMRADamora Therapeutics INC—NEWNew buy
27RLMDRelmada Therapeutics INC—NEWNew buy
28UPBUpstream Bio INC—EXITSold out
29TENXTenax Therapeutics INC—NEWNew buy
30ANLAdlai Nortye Ltd-adr—NEWNew buy
31IPSCCentury Therapeutics INC—NEWNew buy
32KRROKorro Bio INC—NEWNew buy
33ANROAlto Neuroscience INC—NEWNew buy
34XFORX4 Pharmaceuticals INC—NEWNew buy
35✓ Casi Pharmaceuticals INC—EXITSold out

FAQ

What is Venrock Adviser, LLC and what type of investor is it?
Venrock Adviser, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $2.7B, spread across 33 disclosed positions.
What are Venrock Adviser, LLC's largest equity positions?
Based on the latest 13F filing, Venrock Adviser, LLC's top holdings by market value are: 1. Apogee Therapeutics INC (APGE) — $714.9M (26.7%) 2. Erasca INC (ERAS) — $265.1M (9.9%) 3. Oruka Therapeutics INC (ORKA) — $203.5M (7.6%) 4. Spyre Therapeutics INC (SYRE) — $185.9M (6.9%) 5. Kalvista Pharmaceuticals INC (4XC1) — $130.3M (4.9%)
What changes did Venrock Adviser, LLC make in its most recent portfolio filing?
In the latest reported quarter, Venrock Adviser, LLC made 22 notable position adjustments: 8 new positions were initiated, 6 existing holdings were added to, 6 positions were partially reduced, and 2 were completely exited. The largest of these moves: New buy: Damora Therapeutics INC (DMRA); New buy: Relmada Therapeutics INC (RLMD); Sold out: Upstream Bio INC (UPB); New buy: Tenax Therapeutics INC (TENX); New buy: Adlai Nortye Ltd-adr (ANL)
What sectors does Venrock Adviser, LLC focus on?
Sector breakdown data is not yet available for Venrock Adviser, LLC. Check back after the next 13F processing cycle.

Peer Institutions

Institutions with a similar AUM

MM

Main Management ETF Advisors, LLC

Total reported value

$2.7B

116 stks

2026-03-31

Concentration47.9
Portfolio Stability46.8
Sector conviction95.5

AUM within 0.0% of this institution

View detail
AI

Aster Investment Management Co INC

Total reported value

$2.7B

149 stks

2013-06-30

Concentration5.2
Portfolio Stability0.0
Sector conviction88.7

AUM within 0.1% of this institution

View detail
AI

Allianz Investment Management U.S. LLC

Total reported value

$2.7B

65 stks

2025-09-30

Concentration100.0
Portfolio Stability42.2
Sector conviction0.0

AUM within 0.1% of this institution

View detail

Similar Holdings Style

Institutions with overlapping top holdings

RC

Remedium Capital Partners, LLC

Total reported value

$281.2M

6 stks

2026-03-31

Concentration86.3
Portfolio Stability51.1
Sector conviction0.0

3 of the top 5 holdings overlap, including Oruka Therapeutics INC

View detail
AA

Affinity Asset Advisors, LLC

Total reported value

$1.9B

105 stks

2026-03-31

Concentration10.4
Portfolio Stability77.9
Sector conviction100.0

2 of the top 5 holdings overlap, including Apogee Therapeutics INC

View detail
FF

Fairmount Funds Management LLC

Total reported value

$1.4B

12 stks

2026-03-31

Concentration49.3
Portfolio Stability72.5
Sector conviction0.0

2 of the top 5 holdings overlap, including Spyre Therapeutics INC

View detail